Recent advances in the development of cyclin-dependent kinase 7 inhibitors
Author:
Funder
Tianjin University of Science and Technology
ParisDescartes University for permanent
Publisher
Elsevier BV
Subject
Organic Chemistry,Drug Discovery,Pharmacology,General Medicine
Reference68 articles.
1. The target landscape of clinical kinase drugs;Klaeger;Science,2017
2. Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis;Mogul;Ann. Pharmacother.,2019
3. Real-world experience with tofacitinib for treatment of rheumatoid arthritis;Caporali;Clin. Exp. Rheumatol.,2019
4. Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date;Dasso;Clin. Ophthalmol.,2018
5. Sirolimus and mTOR inhibitors: a review of side effects and specific management in solid organ transplantation;Nguyen;Drug Saf.,2019
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Protein engineering enables a soakable crystal form of human CDK7 primed for high-throughput crystallography and structure-based drug design;Structure;2024-08
2. Cyclin-dependent kinase 7 (CDK7) inhibitors as a novel therapeutic strategy for different molecular types of breast cancer;British Journal of Cancer;2024-02-14
3. Antitumor Activity of s-Triazine Derivatives: A Systematic Review;Molecules;2023-05-23
4. A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022);Expert Opinion on Therapeutic Patents;2023-02-01
5. CDK7-dependent transcriptional addiction in bone and soft tissue sarcomas: Present and Future;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2022-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3